» Articles » PMID: 1761118

Has the Incidence of Multiple Myeloma in Old Age Been Underestimated? The Myeloma Project of Health Region I in Norway. I

Overview
Journal Eur J Haematol
Specialty Hematology
Date 1991 Nov 1
PMID 1761118
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

All patients in the region with newly discovered M components were registered from 15 Aug. 1984-31 Dec. 1986. Among a total of 393 patients enrolled, 162 had multiple myeloma (MM). The incidence rate was 6.6 per 100,000 population per year (age-adjusted to the European standard population), which is somewhat higher than previous reports based on hospital and autopsy records. In particular, the incidence rate was higher in the greater than 70 age group. Thus, the median age was 72 yr, which is the highest reported. As many as 71 (44%) of the 162 MM patients were asymptomatic; these asymptomatic patients had the same age distribution as the symptomatic ones. The stage distribution, occurrence of risk factors, response to chemotherapy, response duration and survival were similar in the age groups below and above the median and, in multivariate survival analysis, age was not an independent risk factor.

Citing Articles

More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis.

Lu J, Lu J, Chen W, Wang J, Huo Y, Hou J Drug Des Devel Ther. 2016; 10:3673-3679.

PMID: 27877018 PMC: 5108500. DOI: 10.2147/DDDT.S100062.


Targeted treatments for multiple myeloma: specific role of carfilzomib.

Sugumar D, Keller J, Vij R Pharmgenomics Pers Med. 2015; 8:23-33.

PMID: 25691814 PMC: 4325627. DOI: 10.2147/PGPM.S39085.


Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic.

Turesson I, Velez R, Kristinsson S, Landgren O Mayo Clin Proc. 2010; 85(3):225-30.

PMID: 20194150 PMC: 2843108. DOI: 10.4065/mcp.2009.0426.


Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.

Ludwig H, Durie B, Bolejack V, Turesson I, Kyle R, Blade J Blood. 2008; 111(8):4039-47.

PMID: 18268097 PMC: 4259800. DOI: 10.1182/blood-2007-03-081018.


Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations.

Wisloff F, Gulbrandsen N, Nord E Pharmacoeconomics. 2000; 16(4):329-41.

PMID: 10623362 DOI: 10.2165/00019053-199916040-00002.